Replies to post #796252 on NorthWest Biotherapeutics Inc (NWBO)

[alphapuppy]

Weird no mention of UCLA in this extensive review. Wonder why?

[hankmanhub]

In September 2025, Japan’s Zeon Corporation announced its acquisition of Curate Biosciences’ Deterministic Cell Separation (DCS™) IP and integration into Edge Precision’s micro-molding lines for ZEONEX®/ZEONOR® cyclo-olefin polymer (COP) cartridges.

This event completed the physical supply chain for Eden’s consumables.

Zeon now controls every layer of Eden’s cartridge architecture—the polymer chemistry, the precision tooling, and the deterministic microfluidic geometry that purifies monocytes with gentle, reproducible physics.

Please elaborate on the relationship, if any, between Zeon and NWBO - other than as unrelated supplier/consumer on the open market. This is not guarantee of supply to NWBO.

[Doc logic]

ilovetech,

Just some clarifications. First, the Swiss approval was not for commercial production but was mistakenly (or not totally) read and promoted to be that. The court decision in that situation reflected a “should have known better but no proof of malfeasance” judgment with small fine. I think the judge probably thought investors should have known better too.
Next, the first iteration of Flaskworks was known as Microden and this was later modified into what became the Eden architecture. There may be other points to clarify but these stood out a little more. Best wishes.